Stocktoria

TriSalus Life Sciences, Inc. TLSI

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-12-18

TriSalus Life Sciences, Inc. statistics & valuation

Market cap$290.5M
P / S6.4×
Net margin-86.9%
FCF margin-41.9%
Net debt$12.6M
Enterprise value USD$303.1M
Earnings yield EBIT/EV-8.9%
Return on capital-113.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-380.60% -320.70% -102.10% -86.90% 20212022202320242025
Gross margin (%)
81.80% 85.90% 86.10% 84.60% 20212022202320242025
Operating margin (%)
-293.90% -294.30% -122.90% -59.70% 20212022202320242025
Return on equity (%)
20212022202320242025
Shares outstanding
347926 26.4M 31.3M 50.0M 20212022202320242025
Net debt ($)
-$11.8M $13.6M $12.6M 20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
1.90% -214.50% -241.30% -125.30% -111.00% 20212022202320242025
Free cash flow margin (%)
-265.90% -276.40% -139.90% -41.90% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$161.55 -$6.77 -$1.31 -$1.84 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Gross margin84.6%86.1%85.9%81.8%—
Operating margin-59.7%-122.9%-294.3%-293.9%—
Net margin-86.9%-102.1%-320.7%-380.6%—
FCF margin-41.9%-139.9%-276.4%-265.9%—
Return on assets-111.0%-125.3%-241.3%-214.5%1.9%
Return on equity115.8%116.0%219.3%26.6%-3.7%
Debt / equity-0.98×-0.85×-0.00×——
Current ratio2.802.021.420.530.33

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.